Investing.com — Biogen Inc. (NASDAQ: NASDAQ:BIIB) saw its shares open higher this morning at $199.99 following a positive update on its lupus drug development. The initial enthusiasm was driven by the announcement of promising results from the Phase 3 PHOENYCS GO study.
Despite the promising readout and initial gain, Biogen’s stock is currently down 0.6% at $194.66 a share.
The trial, conducted in partnership with UCB, focused on dapirolizumab pegol, an anti-CD40L asset with a unique mechanism of action in treating systemic lupus erythematosus (SLE).
The PHOENYCS GO study met its primary endpoint, demonstrating an improvement compared to placebo, with RCB Capital analysts noting that it showed clinical benefits across key secondary endpoints related to disease activity and flares.
While detailed results are yet to be presented at a forthcoming medical congress, the study’s success marks a significant milestone for Biogen’s pipeline.
RBC Capital notes that while the positive data is encouraging, the timelines for significant revenue impact remain extended.
They predict that “dapirolizumab pegol could potentially reach the market in 2029/2030” following additional Phase 3 studies and regulatory approvals.
A second Phase 3 study, PHOENICS FLY, is scheduled for 2024, with results anticipated in the following years.
The analysts at RBC are optimistic, stating that today’s announcement “should generate some excitement” for Biogen’s pipeline, though they acknowledge that the immediate stock dynamics are still largely influenced by Leqembi uptake.
The bank maintained an Outperform rating on Biogen with a price target of $292.00, reflecting their belief in the company’s long-term potential despite current market fluctuations.
